Annals of surgical treatment and research · 2026
Comparison of postoperative survival after neoadjuvant treatment versus upfront surgery in resected pancreatic ductal adenocarcinoma: a propensity score matching analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jang Wonjun, Jung Hye-Sol, Han Youngmin, Chae Yoonsoo, Seo Younsoo, Lee Inhyuck, Cho Young Jae, Choi Go-Won, Park Joon Seong, Jang Jin-Young, Kwon Wooil
Аннотация
PURPOSE: Evidence regarding long-term prognosis after surgery by pathological stage in pancreatic ductal adenocarcinoma (PDAC) patients following neoadjuvant treatment (NAT) remains limited.
METHODS: 757 patients who underwent PDAC resection between 2017 and 2021 were analyzed retrospectively. Among them, 262 received NAT followed by surgery (NAT group) and 415 underwent upfront surgery (UFS group). Propensity score matching (PSM) was performed for balanced comparison using the following variables: age, sex, American Society of Anesthesiologists physical status class, and adjuvant treatment.
RESULTS: After PSM, the UFS group showed higher postoperative CA 19-9, larger tumors, less advanced initial clinical stage, but more advanced pathological stage and fewer positive lymph nodes compared with the NAT group. Median overall survival (OS) was similar between groups (NAT vs. UFS: 35 vs. 34 months, P = 0.88). In stage IA, UFS patients had longer OS compared to NAT (not reached vs. 42 months, P = 0.037). No significant OS differences were observed at stages IB, IIA, IIB, and III.
CONCLUSION: Postoperative survival did not differ between NAT and UFS groups when stratified by pathological stage, except for stage IA where UFS showed better outcomes.
METHODS: 757 patients who underwent PDAC resection between 2017 and 2021 were analyzed retrospectively. Among them, 262 received NAT followed by surgery (NAT group) and 415 underwent upfront surgery (UFS group). Propensity score matching (PSM) was performed for balanced comparison using the following variables: age, sex, American Society of Anesthesiologists physical status class, and adjuvant treatment.
RESULTS: After PSM, the UFS group showed higher postoperative CA 19-9, larger tumors, less advanced initial clinical stage, but more advanced pathological stage and fewer positive lymph nodes compared with the NAT group. Median overall survival (OS) was similar between groups (NAT vs. UFS: 35 vs. 34 months, P = 0.88). In stage IA, UFS patients had longer OS compared to NAT (not reached vs. 42 months, P = 0.037). No significant OS differences were observed at stages IB, IIA, IIB, and III.
CONCLUSION: Postoperative survival did not differ between NAT and UFS groups when stratified by pathological stage, except for stage IA where UFS showed better outcomes.